Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220636 · ClinicalTrials.gov registry record · Phase 4
Abilify as an Adjunctive Treatment for Refractory Depression
A Phase 4 study of Depressive Disorder, Major, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00220636: Completed Phase 4 study of Depressive Disorder, Major, sponsored by St. Luke's-Roosevelt Hospital Center.
NCT00220636 is a Phase 4 study of Depressive Disorder, Major that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 15 participants, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00220636, a Phase 4 study of Depressive Disorder, Major, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. It is hypothesized that patients' functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication.
Primary Outcome
Clinician rated measure of depression, mean score; this study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (\>50% decrease) Remission (score\<=7) Outcome is the number of these subjects whose depression "responded" after treatment with aripiprazole, which means a 50% or greater decrease in Hamilton Depression Rat
Conditions Studied
Interventions
- DRUG Aripiprazole
Study Locations (1)
New York
- Depression Evaluation Service, NY State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
What the finished NCT00220636 record still lists
NCT00220636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00220636 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00220636 about?
NCT00220636 is a clinical study titled "Abilify as an Adjunctive Treatment for Refractory Depression". This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. It is hypothesized that patie...
What is the current status of trial NCT00220636?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2005-03. Estimated completion is 2008-01.
What conditions does trial NCT00220636 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT00220636?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00220636?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00220636 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00220636's enrollment target sits among peer trials
15 52nd of 52 higher than 1 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
RECRUITING
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
RECRUITING · NA
-
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
RECRUITING · NA
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia